Norsk
KEY FIGURES
116
NEW INVENTIONS
5
BILLION NOK COMBINED VALUE
OF PORTFOLIO COMPANIES
15
NEW LICENSE AGREEMENTS
60
NEW PATENT APPLICATIONS
148
NEW CLINICAL STUDY AGREEMENTS
440
ONGOING CLINICAL STUDIES
2
NEW COMPANIES ESTABLISHED
24
MILLION NOK TO
NEW RESEARCH AND INNOVATION
670
MILLION NOK
PRIVATE CAPITAL RAISED
A word from the CEO
2024 ended on a positive note. Zelluna and Ultimovacs merged in an exciting collaboration to advance their precision cell therapies into clinical trials. This merger was strengthened by over NOK 50 million in fresh capital from private investors, including Inven2. Other promising startups from our portfolio also benefited from positive recapitalisation processes supported by public and private sources throughout the year.
Read more
Innovation
– how do you take your research to market?
Inven2’s main area of focus is taking research results and turning them into a product or service in a market. This is done through a value chain that starts with idea hunting and marketing of Inven2’s services aimed at researchers at the University of Oslo and Oslo University Hospital.
Read moreCLINICAL TRIALS ARE THE KEY TO MEDICAL DEVELOPMENT
Clinical trials involve testing new drugs and medical equipment on human subjects. Clinical trials can be conducted on both healthy volunteers and patients.
Read more
The board of directors
Inven2’s mandate is to commercialise research on behalf of our owners: the University of Oslo, Oslo University Hospital and the South-Eastern Norway Regional Health Authority.
Our board has broad insight into different fields of research, commercialisation, innovation, start-ups and knowledge-intensive business services.
Employee representative is Nina Løvbakken, Head of Accounting in Inven2.
Tom Pike chairs the board.
About inven2
We turn research and knowledge into products and services that benefit society
Research and knowledge are the keys to addressing global challenges relating to health, climate and the environment. Highly capable researchers and clinicians from larger parts Norway report their ideas and discoveries to us. We develop and manage these ideas, and proceed with the ones that can be transformed into products that benefit society.
We have started businesses that develop better cancer therapies, combat antibiotic resistance and identify security breaches in complex IT systems. Two-thirds of our businesses and licences are in the field of life science, since the scientific community we represent is particularly strong in that field.
Another important area for us is to administer agreements on clinical trials on behalf of the hospitals in our region and in the northern part of Norway. We make active endeavours to get more international companies to carry out their clinical trials in Norway. That way, more innovative treatment can benefit more patients in Norway.
Inven2 is a limited company owned by the University of Oslo and Oslo University Hospital. Inven2 currently has 31 employees.
Portfolio businesses
Inven2 has a portfolio comprising about 50 companies. 2 new companies were established in 2024. Together, the companies are worth around NOK 5 billion.
The companies raised a total of NOK 670 million for development purposes in 2024. At the same time, NOK 24 million was returned to research and innovation through lisence income or sale of shares.
Portfolio
Products
Inven2 want to make a difference by transforming research and knowledge into products and services for the benefit of society. We have contributed to the launching of many products and services. Here is a selection.
Ecosystem
Inven2 is part of a vital, ever-growing ecosystem in research and development. The area near Inven2’s premises in Oslo Science Park is home to a number of clusters and incubators, as well as the University of Oslo and Oslo University Hospital.
Read more